Sofinnova Investments, Inc. Argenx Se Transaction History

Sofinnova Investments, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Aug 14, 2024	BUY	$356.95 - $413.29 $53.3 Million - $61.7 Million	149,300 New	149,300 $58.8 Million
Q1 2024 May 15, 2024	BUY	$356.95 - $413.29 $37.3 Million - $43.2 Million	104,579 Added 233.85%	149,300 $58.8 Million
Q4 2023 Aug 15, 2024	BUY	$338.91 - $506.01 $15.2 Million - $22.6 Million	44,721 New	44,721 $17 Million
Q4 2023 Feb 12, 2024	BUY	$338.91 - $506.01 $1.63 Million - $2.43 Million	4,800 Added 12.02%	44,721 $17 Million
Q2 2023 Aug 14, 2023	BUY	$360.14 - $422.58 $14.4 Million - $16.9 Million	39,921 New	39,921 $15.6 Million
Q2 2022 Aug 15, 2022	BUY	$269.58 - $378.88 $4.04 Million - $5.68 Million	15,000 New	15,000 $5.68 Million

371

31.4M

303K

429K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $30B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Sofinnova Investments, Inc., based on Form 13F filings with the SEC.

Stay updated on Sofinnova Investments, Inc. with notifications on news.